68 results
8-K
EX-99.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
expectations, plans and prospects for Eliem following the consummation of the acquisition of Tenet by Eliem; the anticipated benefits of the acquisition … ; the anticipated cash runway of the combined company; expectations regarding TNT119’s therapeutic benefits, clinical potential and clinical development
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
investigation;
perceived risks and benefits of the product candidate under study;
Tenet’s ability to recruit clinical trial investigators with the appropriate … to Regulatory Matters
Tenet has received orphan drug designation for TNT119 for the treatment of MN, but it may be unable to realize the benefits
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
as may be necessary to afford Buyer or any Affiliate of Buyer with the benefits of such Non-Transferable Asset as if Buyer or any such Affiliate were
8-K
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
of Tenet by Eliem; the anticipated benefits of the acquisition; the strategy, anticipated milestones and key inflection points of the combined company … benefits, clinical potential and clinical development, and anticipated timelines for initiating clinical trials of TNT119, including initiating Phase
8-K
EX-99.4
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within
8-K
EX-99.2
npgixhse24
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
aredwhi1zx6 swd
26 Jun 24
Submission of Matters to a Vote of Security Holders
4:23pm
DEFA14A
r46up5ujyu2ptdc3l10x
14 Jun 24
Additional proxy soliciting materials
5:02pm
DEFA14A
z9grur
12 Jun 24
Additional proxy soliciting materials
4:42pm
8-K
EX-10.1
idl5nn3llbo
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
8-K
xatbwq4
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
DEFM14A
oh8xxcw8af tsxos
4 Jun 24
Proxy related to merger
8:00am
PREM14A
jxj2hbg
17 May 24
Preliminary proxy related to merger
4:36pm
10-K/A
umunmgi7 trhe
29 Apr 24
Annual report (amended)
4:02pm
DEFA14A
mjhsvfrg
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-10.5
e3tvg6 woy5f22a
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-2.1
9pnv2x3
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.3
9e00a2yhezr6dps
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am